Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That probably wasn't the last, With the A/S increase to 500 mill coming in Sep there may be even lower priced "gifts" coming our way...
The whirlwind tour was last summer, 2012, I attended the Boston session with Mr. Infinity
from the early days I believe >30 million were held in tight hands; and the 35 million that the claim sellers accepted at $0.01/share will, IMHO, also be held tight for quite some time...
And back at you, Sir! Hoping for a productive summer season for WOLV this year. Bruce and Lee ought to be commended for their foresight. It doesn't get much better than that. I suspect that once the dust has settled over Barkerville's NI43-101, and there's some more progress reported by the Omineca neighbors, we're going to sit very pretty...
We are all fortunate to have gotten in so early. Maybe a bit ahead of their time, but I can see them setting a new standard industrywide, bit by bit..until the watershed moment comes ...
The same 5 analysts that yelled victory for SGYP and their "superior" drug after comparing side effects with linaclotide when less than a dozen patients had been dosed with plecanatide ?
And Aegis Capital, the underwriter firm from the SGYP share offering? Definitely all objective & completely altruistic advice, who could think otherwise?
Look no further my friend & let not your heart be troubled by my frivolously heretical thoughts, you are in good hands and the biotech lady of luck will soon smile upon you :)
I can (& tried to) fix ignorant, but I can't fix stupid.
good luck. you're going to need it.
nature includes people. people's metabolisms can be quite different. all that the pirates (e.g. Teva) need to do is keep screening urine samples until they find it (the SNP mentioned in the article, you may want to read up: http://en.wikipedia.org/wiki/Single-nucleotide_polymorphism). They only need to find it once. Since the IP of plecanatide (contrary to Linaclotide, which is based on method of use patents, SGYP actually has to pay IRWD a royalty on all future plecanatide sales (if any)!) is based on a composition of matter patent, its validity critically depends on that SNP not being found in the future. So you're basically gambling against nature's diversity. Is that a winning bet you would like to take? I don't know about your background, but I've been working in the pharmaceutical industry for a while, and no inlicencing person in a large pharma would want to take that chance. if the (actually pretty succinct) patent analysis was too much "psychobabble" for you to comprehend, you probably shouldn't be invested in the biotech industry to begin with....
I understand your pessimism. It has been a long haul, for sure & it will take some more patience to see the story develop. Heck, it hasn't even started yet. But I have faith in the Costerd brothers that they will see this through & brought to fruition. they are of hardy & resilient mining stock; - think the Brackebusch's ... :)
wrong on all guesses. sure, let's compare notes in a year from now good luck!
...a little useful reading beforehand, indeed! It's usually better to consider the facts first before listening to analyst opinions...
(especially those without full disclosure)
from our peer 'frontiers', a scientist also, I suspect (s. link below). consider its implications. IMHO, very likely the reason they haven't been able to find a development partner yet. a single amino acid mutation, if found in nature or in some patients (and the 'pirates' are very, very good at digging for stuff like that), has the potential to invalidate the plecanatide IP. not a favorable risk/reward ratio at all.
THINK! if it were such a superior drug compared to linaclotide & would overtake linaclotide in the market in a heartbeat, why haven't they found anyone to partner with them for this profit opportunity ? why is the institutional $$ in IRWD ~75% vs. ~17% for SGYP ? ?Surely, you have added up all the $$ it took IRWD to get where they are & extrapolated how much SGYP would have to dilute to get there without a development partner, yes ?
Have you looked at how few patients were actually dosed in the earlier plecanatide studies when the "little to no diarea" claims for plecanatide abounded (check where the hurrah claims/analyst reports came from!) , then compared to how many patients were dosed in their multicenter trial presented at DDW ? the diarea numbers were still somewhat better than linaclotide, but have you noticed how much the margin has shrunk? what, do you think, will the margin be (if any, LOL) once they are at the pivotal, larger patient number stage ?? and we havent' even touched on efficacy yet...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84178830
Not need to get insulting. Just my own humble opinion. No , I am not the moose & no, not totally bullish about linaclotide. Just looking at the facts (like active dose comparison which has a bearing on profitability / competitive edge) & where the institutional / smart money (I.e., probably not yours ) is going. In a way, both SGYP & IRWD got it handed to them by Sucampo (recent OIC indication approval for Amitiza); look at what it did to the Sucampo stock price. The market puts a premium on the OIC market compared to IBS & CIC; - and the FDA accelerated OIC approval indicates the regulators perceive it as the more pressing & unmet medical need as well.
DaMoose, very good assessment. probably more than three times LOL. IRWDs addtl. stock offering might be the last; it's quite a bit less than the debt financing earlier in the year. I'm sure you know the structures of the two drugs; at similar structure / complexity, there's a more than average chance their cost of manufacturing will be in the same ballpark as well; - only problem is that the active dose of plecanatide (3 mg) is roughly about 20x the dose of linaclotide in the North American market (~10x in the European market). good luck competing with linaclotide. SGYP will have to sell their drug not at, but possibly under cost to compete LOL. profits will be hard to come by ... plus they're even more behind in development for the bigger/more profit-relevant IBS-C market and will only be able to compete in the CIC market initially. explains the institutional (i.e., smart money) ownership difference (~75% for IRWD, only ~17% for SGYP). and still no commercial partnership on the horizon for SGYP...just slowly sinking into the swamp under the cost load....
would an FMC licence/status give you the right to sample/drill on someone else's placer claims? I couldn't find any mineral tenures on the BC MTO website belonging to Wolverine Exploration...
Could well be. watch what the central banks DO, not what they say. If you haven't already, listen to Robin Griffith (Cazenove Bank London) Interview(s) on King World News...
nah, looks like they're gone back into hibernation until 2014...
IMHO, I believe the company has realized that the shoe-stringing drill-a-hole-or-two at shallow depths approach is over & they need to get serious & look deeper; they are certainly trying to conserve resources...
if they can find a JV partner or other funding sources, the story can continue...
http://www.siliconinvestor.com/readmsg.aspx?msgid=28543526
got a bunch, too. would have liked to get more to average down some more, but looks like someone beat me to the last batch of 006s on Fri...
wrong. according to the SEC filing, he sold 225,403 shares @ 0.005 of his 3,845,593 shares and afterwards owned 3,620,190 shares; - on my pocket calculator, he sold only 5.9% of his share count and still owns a sizeable chunk of the float.
guessing ~ 50-60 million at this time, maybe the moderators can shed some light on this?
you also conveniently neglected to mention he bought 600,000 shares of WOLV on 07/31/2012 at a price of $0.01; - quite a vote of confidence given how little he was paid as WOLV executive this year, wouldn't you agree?
http://www.sec.gov/Archives/edgar/data/0001424404/000142440412000004/0001424404-12-000004-index.htm
http://www.sec.gov/Archives/edgar/data/0001424404/000142440412000003/0001424404-12-000003-index.htm
200,000 @ 0.009 ask today. Early tax loss selling perhaps ...?
yup. ~8.6% insider ownership and 10+ % institutional ownership (Swiss fund); good enough for me.
talk about a bottom-feeder low ball offer; doubt that they will get many takers - I'm not tendering mine, that's for sure
me too :)
intriguing, to me at least. BULM management are no fools. look up their track record.
also, its actually ~1.65 million (see below); my bad, sorry for the typo. have an inquiry pending with BULM IR. will post if/when I hear back.
Other Equity Interests held by Bullion
1. 3,000,000 shares of common stock of Pacific Gold Corp.
2. 1,651,000 shares of common stock of Sidney Resources Corporation
3. 2,245,000 shares of common stock of Golden Ibex, Inc.
http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=8391778-4087-355708&SessionID=ZV8TFjaFdFt4d_7
BULM accepted SDRC shares in exchange for metallurgical tests (& was willing to hang on to them, > 1.7 million as of Feb 2012 per: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=75381078&txt2find=bulm ) for a reason. good enough for me.
Eik, some plausible scenarios you're suggesting there, agree. in any event, they don't have much left of the initial 500,000 GBP loan they received. So they have to come back to the market to raise more pretty soon. Promising initial exploration data would make that easier....
repeated requests for updates regarding this matter to the company IR have all remained unanswered to date. hmmmmm....
actually, I believe the grid one 1st priority targets were drilled, and not grid 2 (which has the highest surface grab samples & the malachite outcroppings)...
ask under a dime. ready to load up ? :)
touche, huh ? thanks for proving my point.
oops the "paid compensation sign" disappeared from your posts on the WOLV board - what's up with that? your customer refused to pay since your smear campaign failed to bring down the PPS where they wanted it to be LMAO
...or George Soros
10K late, now ~ 2 weeks behind deadline of the 12b-25 rule delay notice filed at the end of March.
maybe something brewing behind the scenes ??
maybe this will benefit WOLV if it gets passed quickly, especially in regard to facilitating investing for both accredited as well as non-accredited investors:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74605219
and here. :)
good point, Doubloon. had bought it earlier because of their Blue River tantalum/niobium deposit; - niobium being rated 8, second highest rating on the BGS 2011 critical elements risk list (http://www.bgs.ac.uk/downloads/start.cfm?id=2063). With the apparently substantial REE deposit, downright undervalued IMHO.
nevertheless, those preliminary ural exploration data from the eighties must be somewhat promising IMO...you don't just get ~ 1 million USD from an investor out of the blue. IMO, tungsten & molybdenum will become very hot commodities once China tightens the export noose; - China used 55 percent of all of the world’s metals last year. (read: http://rareearthinvestingnews.com/2527/the-future-of-critical-metals/ ). For a few months after the R/S, I was able to soak up some shares here and there at the bid or slightly above. After the last quarterly that listed the UK funding, not anymore - FWIW.
some UK investor gave them 500,000 GBP per last filing for geological licence; so something's going on in the background. willing to wait this one out; tungsten & molybdenum ....